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Skeletal-related events (SREs), which include radiation to the bone (RtB), can occur among
patients with bone metastasis (BM). There is a recognized potential for misclassification of
RtB when using claims data. We compared alternative measures of RtB to better under-
stand their impact on SRE prevalence and SRE-related mortality.
Methods and materials
We analyzed data for stage IV prostate cancer (PCa) cases identified between 2005 and
2009 in the Surveillance, Epidemiology, and End Results registry linked with Medicare
claims. We created two measures of RtB: 1) a literature-based measure requiring the pres-
ence of a prior claim with a BM code; 2) a new measure requiring either that the BM code
coincided with the radiation episode or that the duration of the radiation episode was less
than or equal to 4 weeks. We estimated adjusted hazard ratios of an SRE using both mea-
sures among stratified samples: no metastasis (M0), metastasis to bone (M1b) and other
sites (M1c).
Results
The study sample included 5,074 men with stage IV PCa (median age 77 years), of whom
22% had M0, 54% had M1b, and 24% had M1c disease at time of PCa diagnosis. Based on
Approaches 1 and 2, the proportion with probable RtB was 5% and 8% among M0, 30% and
30% among M1b, and 25% and 27% among M1c patients. Among M0 patients, the adjusted







Citation: Onukwugha E, Kwok Y, Ciezki JP, Yong C,
Plaisant C, Reddy CA, et al. (2017) Skeletal-related
events and mortality among men diagnosed with
advanced prostate cancer: The impact of alternative
measures of radiation to the bone. PLoS ONE 12
(4): e0175956. https://doi.org/10.1371/journal.
pone.0175956
Editor: Adriano Angelucci, University of L’Aquila,
ITALY
Received: September 3, 2016
Accepted: April 3, 2017
Published: April 18, 2017
Copyright: © 2017 Onukwugha et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: There are some
access restrictions that apply to the data underlying
the reported findings. The SEER-Medicare data
used in this study were obtained from NCI and
were approved for use in this particular project.
Investigators who seek to use SEER-Medicare data
should request approval from NCI by submitting an
Application Form, Data User Agreement, and
documentation of IRB approval. For additional
information about gaining access to SEER-
Medicare data, please contact Yanisko, Elaine
hazard ratio (AHR) associated with an SRE was 1.27 when using Approach 1 (95% confi-
dence interval, CI: 0.95–1.7) and 1.49 when using Approach 2 (95% CI: 1.14–1.96). How-
ever, the impact of SREs on mortality did not differ between both approaches among M1b
and M1c patients.
Conclusion
We found that alternative measures used to define RtB as SRE in claims data impact con-
clusions regarding the effect of SREs on mortality among M0 but not M1 patients.
Introduction
The 5-year survival for localized and regional prostate cancer (PCa) is 100%, but only 28% for
men with metastatic disease.[1] In PCa, bone is the most common site of metastasis and affects
up to 8 in 10 men with metastatic disease.[2] Patients with bone metastasis (BM) are at risk of
developing skeletal complications known as skeletal-related events (SREs), which typically
include pathological fractures, spinal cord compression, bone surgery and palliative radiation
to the bone (RtB). SREs have been reported to be associated with impaired health-related qual-
ity of life, increased morbidity, and substantial economic burden.[3–6] A number of studies
have also shown that SREs negatively affect survival [7, 8] and that the impact on survival var-
ies by the type of SRE.[9] As a cluster of events, SREs occur in approximately 50–60% of
patients with BM secondary to PCa, with RtB commonly reported as the most prevalent SRE
subtype followed by pathological fractures.[10]
The estimated prevalence of each SRE subtype has varied across studies due to differences
in study populations and methodology. RtB has been reported to occur in 60–90% of PCa
patients with BM.[5, 7, 8] Although population-based studies that utilize administrative claims
data offer the advantage of large sample sizes and evidence that reflects real-world clinical
practice, they are often limited by the lack of specific clinical information such as laboratory
test results or disease progression. In claims-based observational studies that examine RtB,
procedural codes are used to identify RtB. Generally, patients are first identified to have BM
using diagnosis codes, and all radiation episodes that occur on or after claims-based evidence
of BM are considered RtB. A drawback of this approach is that claims-based measures of BM
based on diagnosis codes have limited validity for identifying patients with BM. Further, the
procedural codes for radiation do not specify the site of radiation [11] and hence cannot differ-
entiate between palliative radiation therapy to the bone and radiation therapy to the prostate
gland or other anatomic sites. As a result, counting all radiation episodes as RtB could result in
an overestimation of RtB since some patients who only received radiation targeted to other
sites would be misclassified as having received RtB.
There is currently no validated algorithm for identifying RtB using claims data. To our
knowledge, there is limited evidence regarding the implications of various decisions made dur-
ing the development of claims-based measures for identifying RtB. As current technological
developments facilitate the availability of larger, linked datasets, it will become increasingly
important to understand the implications of fundamental decisions that are made when creat-
ing variables for analysis using claims data. National Comprehensive Cancer Network guide-
lines recommend 8 to 9 weeks of radiation therapy to the prostate gland.[12] In a previous
study conducted on patients with BM secondary to pancreatic cancer, the median duration for
radiation to the bone was 15 days.[13] Based on the practice of administering shorter duration
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of radiation therapy for palliation to the bone compared to treatment to the prostate gland, we
sought to determine if the length of radiation therapy may be informative for identifying RtB
using claims data. The objective of this proof-of-concept study was to investigate the preva-




This was a retrospective cohort analysis of linked Surveillance, Epidemiology, and End Results
(SEER) cancer registry and Medicare claims data on men aged 66 years or older and diagnosed
with incident American Joint Committee on Cancer Tumor-Node-Metastasis (AJCC-TNM)
stage IV prostate cancer between 2005 and 2009. The additional inclusion criteria were: 1) con-
tinuous enrollment in Medicare Parts A and B during the 12 months prior to and including
the month of diagnosis; 2) not enrolled in a Medicare Advantage plan during the 12 months
pre-diagnosis period; 3) no history of other cancers within 5 years prior to PCa diagnosis; 4) at
least 30 days of follow-up; and 5) non-missing information from SEER data regarding the site
of metastasis at diagnosis. Using collaborative stage information from SEER, patients were cat-
egorized into mutually exclusive groups as follows: 1) no distant metastasis (M0); 2) metastasis
to the bone (M1b); and 3) metastasis to other sites (M1c). Men with metastasis to distant
lymph node only (M1a) were excluded as the small sample size (N = 204) did not permit sepa-
rate analysis; and their different prognosis did not justify grouping them with the M0, M1b, or
M1c groups.
Measures
The outcome of interest was all-cause mortality. The primary independent variable was evi-
dence of any skeletal-related event (SRE) occurrence as identified from inpatient, carrier, and
outpatient claims using the relevant diagnosis and procedure codes. The referent group was
men who did not experience any SRE following PCa diagnosis. Similar to the definition of
SREs in clinical trials conducted in men with bone metastasis secondary to PCa [14–16], SREs
identified in this study included four SRE subtypes: fractures, spinal cord compression, bone
surgery, or radiation to the bone (RtB). RtB included external beam radiation therapy, radio-
pharmaceutical therapy, intensity modulated radiotherapy and stereotactic radiosurgery.
Given the lack of a validated measure for identifying RtB in administrative claims, we used
two measures to identify RtB in this study and compared the mortality impact of SREs using
both measures. The only difference between the SRE measures was the definition for RtB.
Approach 1 for identifying RtB was based on prior literature.[17] Approach 2 was developed
based on more stringent use of the BM diagnosis codes in claims data and clinical input
regarding shorter length of RtB compared to radiation to the prostate gland. Previous findings
using the EventFlow[18] data visualization software suggested that the length of radiation ther-
apy may be useful in distinguishing between RtB and radiation to the prostate gland during
the time period covered by this SEER Medicare dataset.[19] The length/duration of radiation
episode was determined by consolidating consecutive radiation claims with a gap of fewer
than 7 days. In Approach 1, RtB was identified by any radiation claim that occurred after a
claim with a bone metastasis (BM) ICD-9 diagnosis code of 198.5 (secondary malignant neo-
plasm of bone and bone marrow). In Approach 2, RtB was identified based on a BM diagnosis
code directly coinciding with the period of the radiation episode OR the duration of the radia-
tion episode was less than or equal to 4 weeks. We selected a 4-week maximum duration
because the duration of radiation therapy targeting the bone tends to be shorter than the
Skeletal-related events and mortality
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duration of radiation to the prostate tissue, where radiation to the bone ranges between 1–30
days and radiation to the prostate tissue spans 7 to 8 weeks.[13, 20]
Statistical analysis
Cox proportional hazards (PH) regression models were used to examine the association
between SREs and all-cause mortality across the two measures for identifying SREs. Interac-
tion terms between the SRE indicator and the binary indicators for sites of metastasis at diag-
nosis were statistically significant, indicating that the mortality impact of SREs depended on
the initial site of metastasis. Hence, we examined the mortality impact of SREs in the M0,
M1b, and M1c subpopulations.
The regression models included the following potentially confounding patient-level base-
line variables: demographic factors (age, race, marital status, urban residence), clinical factors
(tumor differentiation), at least 1 month of state buy-in, region of SEER registry, and year of
diagnosis. Claims data from the 12 months prior to diagnosis were used to obtain other poten-
tially confounding baseline measures: Charlson Comorbidity Index, presence of osteoporosis,
poor performance status (measured by an indicator for any use of skilled nursing facility, hos-
pitalization, walking aids, wheelchairs, or home oxygen), and the use of preventive services
(measured by an indicator for any bone mineral density test, flu vaccination, prostate-specific
antigen test, or colorectal cancer screening).
Adjusted survival curves were produced for the full sample and stratified samples to exam-
ine the SRE effect graphically.[21] We reported time-invariant adjusted hazard ratios (HRs)
when the PH assumption was not violated, and time-specific HRs in the case of statistically sig-
nificant non-proportional hazards associated with SREs. Survival models were also estimated
with PCa-specific mortality and non-PCa mortality. The cut-off value for statistical signifi-
cance was 0.05. All statistical analysis was conducted using Version 9.3 of the Statistical Analy-
sis Software System. This study was approved by the University of Maryland Baltimore
Institutional Review Board.
Results
The study sample included 5,074 men with stage IV PCa, of whom 22% had M0, 54% had
M1b, and 24% had M1c disease at the time of PCa diagnosis. The median age for the sample
was 77 years. Table 1 shows other sample characteristics, stratified by metastasis status at diag-
nosis. Compared to the M0 sample, the M1b and M1c samples were generally older, had a
higher proportion of non-Hispanic African Americans, and had greater comorbidity burden
as measured by Charlson Comorbidity Index (Table 1). All-cause mortality and PCa-specific
mortality in the full sample were 55% and 31% at a median (mean; min; max) follow up of 579
days (652; 30; 1826). Of the 5,074 men, the proportion who had any fracture, SCC, and BS was
23.5%, 6.4%, and 5.9%. As shown in Table 1, the prevalence of each SRE subtype varied by site
of metastasis at diagnosis.
The proportion who received any radiation therapy in the full sample was 36%. Based on
Approaches 1 and 2, the proportion with probable RtB was 23.0% and 24.3%, respectively
(Table 2). The proportion with any SRE was 40.1% and 41.4%, respectively, for Approaches 1
and 2. The prevalence of probable RtB and any SRE was highest in the M1b population and
lowest in the M0 population. The median times from PCa diagnosis to the first fracture, SCC,
and bone surgery were 146, 322, and 173 days respectively. The median times to the first radia-
tion episode based on Approaches 1 and 2 were 162 days and 145 days, respectively.
Table 3 compares the distribution for episode duration among radiation episodes with and
without BM diagnosis code. For radiation episodes with BM code present, the majority of
Skeletal-related events and mortality
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N Col % N Col % N Col % N Col %
Skeletal-related events
Fracture 1,194 23.5 161 14.4 726 26.6 307 24.9 <0.01
Spinal cord compression (SCC) 322 6.4 35 3.1 194 7.1 93 7.6 <0.01
Bone surgery (Surg) 301 5.9 35 3.1 186 6.8 80 6.5 <0.01
Age <0.01
66–69 954 18.8 407 36.4 364 13.4 183 14.9
70–74 1,064 21.0 312 27.9 533 19.6 219 17.8
75–79 996 19.6 188 16.8 573 21.0 235 19.1
80–84 992 19.6 103 9.2 595 21.8 294 23.9
85+ 1,068 21.1 107 9.6 661 24.3 300 24.4
Race 0.01
Non-Hispanic White 3,881 76.5 882 79.0 2,091 76.7 908 73.8
Non-Hispanic African American 627 12.4 104 9.3 349 12.8 174 14.1
Hispanic 315 6.2 76 6.8 151 5.5 88 7.2
Other 251 5.0 55 4.9 135 5.0 61 5.0
Married 3,090 60.9 786 70.4 1,612 59.1 692 56.2 <0.01
Urban residence 4,502 88.7 1,002 89.7 2,412 88.5 1,088 88.4 0.50
Poorly Differentiated Tumor 3,356 66.1 958 85.8 1,738 63.8 660 53.6 <0.01
Charlson Comorbidity Index <0.01
Zero 2,787 54.9 698 62.5 1,443 52.9 646 52.5
One 991 19.5 230 20.6 508 18.6 253 20.6
Two or higher 864 17.0 141 12.6 505 18.5 218 17.7
Missing 432 8.5 48 4.3 270 9.9 114 9.3
Osteoporosis 49 1.0 NR <1.0 28 1.0 NR <1.0 0.89
Poor performance status proxy* 1,279 25.2 204 18.3 723 26.5 352 28.6 <0.01
Use of preventive services** 3,448 68.0 895 80.1 1,761 64.6 792 64.3 <0.01
State buy-in (at least 1 month) 718 14.2 106 9.5 412 15.1 200 16.3 <0.01
Region of SEER registry 0.02
Northeast 975 19.2 204 18.3 506 18.6 265 21.5
South 948 18.7 207 18.5 493 18.1 248 20.2
Midwest 720 14.2 140 12.5 416 15.3 164 13.3
West 2,431 47.9 566 50.7 1,311 48.1 554 45.0
Year of diagnosis 0.04
2005 1,098 21.6 232 20.8 584 21.4 282 22.9
2006 1,028 20.3 197 17.6 559 20.5 272 22.1
2007 976 19.2 241 21.6 498 18.3 237 19.3
2008 1,004 19.8 229 20.5 547 20.1 228 18.5
2009 968 19.1 218 19.5 538 19.7 212 17.2
NR: not reported due to small cell size (<11), per data use agreement.
*Poor performance status proxy in the 1 year prior to diagnosis was measured by an indicator for any use of SNF, hospitalization, walking aids, wheelchairs,
or home oxygen.
**Preventive services in the 1 year prior to diagnosis was measured by an indicator for any of the following: bone mineral density test, flu vaccination,
prostate-specific antigen test, or colorectal cancer screening.
https://doi.org/10.1371/journal.pone.0175956.t001
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radiation episodes (>70%) were less than or equal to four weeks in duration. For radiation epi-
sodes without a BM code, more than half of the radiation episodes in the M1b and M1c popu-
lations were less than or equal to four weeks in duration. In contrast, among the M0
population, just 11.2% of the radiation episodes without BM code was less than or equal to
four weeks in duration; while 47.8% of the radiation episodes were greater than eight weeks in
duration.
Using Approach 2, there was a statistically significant increased hazard of mortality associ-
ated with an SRE in the full sample (Fig 1A) as well as the M0, M1b and M1c subsamples (Fig
1B, 1C and 1D). Conclusions regarding the mortality impact of SREs varied with the definition
of RtB embedded in Approaches 1 and 2 (Fig 2). Among M0 patients, the adjusted hazard
ratio (AHR) associated with an SRE was 1.27 when using Approach 1 (95% confidence inter-
val: 0.95–1.7) and the AHR was 1.49 when using Approach 2 (95% confidence interval: 1.14–
Table 2. Proportion of patients with palliative radiation to the bone (top) and any skeletal-related
event (bottom) across measures*.
Radiation to the bone**
Approach 1 Approach 2
Stage IV (N = 5,074) 23.0% 24.3%
M0 (n = 1,117) 4.9% 8.0%
M1b (n = 2,726) 29.5% 30.0%
M1c (n = 1,231) 25.1% 26.7%
Any skeletal-related event***
Approach 1 Approach 2
Stage IV (N = 5,074) 40.1% 41.4%
M0 (n = 1,117) 19.8% 22.7%
M1b (n = 2,726) 47.3% 47.8%
M1c (n = 1,231) 42.6% 44.0%
*The 2 measures for measuring radiation to the bone were: 1) Radiation claim occurred concurrent with or
after a claim with a bone metastasis (BM) code; 2) Either BM code directly coincided with the period of the
radiation episode or the duration of the radiation episode was less than or equal to 4 weeks.
** Radiation to the bone included external beam radiation therapy, radiopharmaceutical therapy, intensity
modulated radiotherapy and stereotactic radiosurgery.
***Patients were considered to have a skeletal-related event if they experienced any radiation to the bone,
fracture, spinal cord compression, or bone surgery. The only difference between Approach 1 and 2 was the
definition for probable radiation to the bone.
https://doi.org/10.1371/journal.pone.0175956.t002
Table 3. Distribution for duration of radiation episodes, by presence of bone metastasis (BM) diagno-
sis code during radiation episode.



























n = 843 n = 963 n = 454 n = 38 n = 269 n = 667 n = 120 n = 258
0–4 weeks 32.3% >80% 11.2% >70% 55.8% 87.1% 59.2% 85.3%
>4–6 weeks 12.3% >5% 10.6% NR 13.8% 8.7% 15.8% 8.9%
>6–8 weeks 21.1% <5% 30.4% NR 8.9% 2.6% 13.3% NR
>8 weeks 34.3% <5% 47.8% NR 21.6% 1.7% 11.7% NR
https://doi.org/10.1371/journal.pone.0175956.t003
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1.96). Among M1b patients, the adjusted hazard ratio (AHR) associated with an SRE varied
over time: within one year of diagnosis, it was either below 1 or not statistically significant. At
three years following diagnosis, the AHR was 1.81 when using Approach 1 (95% confidence
interval: 1.52–2.15) and the AHR was 1.77 when using Approach 2 (95% confidence interval:
1.49–2.1). Among M1c patients, the adjusted hazard ratio (AHR) associated with an SRE also
varied over time. The AHR was 0.66 when using Approach 1 (95% confidence interval: 0.56–
0.79) and the AHR was 0.67 when using Approach 2 (95% confidence interval: 0.56–0.79). At
three years following diagnosis, the AHR was 1.5 when using Approach 1 (95% confidence
interval: 1.12–2) and the AHR was 1.68 when using Approach 2 (95% confidence interval:
1.25–2.26).
We investigated the patterns of treatment receipt and survival outcomes in the M1c group
in exploratory analyses. We found higher treatment rates among those with SREs vs. no SREs:
24% vs. 12% (p<0.01) for chemotherapy, and 70% vs. 54% (p<0.01) for luteinizing hormone-
releasing hormone (LHRH) agonists. In the absence of the appropriate measures for examin-
ing disease-specific outcomes (e.g., measures of cancer treatment toxicities such as cardiovas-
cular-specific mortality due to treatment-related toxicities) we examined the broader category
of nonPCa-specific mortality. The AHRs for PCa-related mortality were: 0.79 (0.64–0.98) at 1
year; 1.19 (0.92–1.53) at 2 years; and 1.77 (1.10–2.87) at 3 years. The AHRs for nonPCa-related
mortality were qualitatively similar: 0.52 (0.38–0.70) at 1 year; 1.03 (0.81–1.30) at 2 years; 2.03
(1.37–3.01) at 3 years.
Discussion
Claims data linked with registry information provide the opportunity to investigate clinical
and mortality impacts of SREs. While claims data provide information regarding receipt of
Fig 1. A-D. Direct adjusted survival curves for any SRE (based on Approach 2) in the full sample (Fig 1A), M0
(Fig 1B), M1b (Fig 1C) and M1c (Fig 1D) samples.
https://doi.org/10.1371/journal.pone.0175956.g001
Skeletal-related events and mortality
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Fig 2. Adjusted hazard ratios (95% CI) associated with SREs for all-cause mortality based on
Approaches 1 and 2 in the M0*, M1b** and M1c** samples. The regression models controlled for
patient-level demographic factors (age, race, marital status, urban residence), baseline clinical factors (tumor
Skeletal-related events and mortality
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radiation therapy, they do not confirm whether the radiation was delivered to the prostate
gland or to the bone. This distinction is critical for identifying radiation to the bone (RtB), one
of the events that constitute an SRE. Prior studies [5, 8, 22] have supplemented the claims for
radiation therapy by conditioning on a prior claim with a bone metastasis (BM) diagnosis
code. We required a prior BM code in the first approach and required a concurrent BM code
or a shorter duration of radiation therapy in the second approach. Using both measures, we
investigated the mortality impact of SREs in subsamples defined by M stage: M0, M1b, and
M1c. This difference in incident diagnosis substage was important because patients with
metastasis at diagnosis would not receive radiation for curative intent while the same conclu-
sion could not be drawn for patients with M0 disease.
We found that the conclusion regarding the mortality impact of SREs varied with Approach
1 and Approach 2 among the M0 group but did not vary among the M1 subgroups. The use of
Approach 1 did not indicate a statistically significant mortality impact of SREs while use of
Approach 2 indicated a statistically significant mortality impact of SREs. It is likely that the
RtB instances identified in the M0 group were not limited to receipt of palliative radiation
therapy. From Table 3, a minority (i.e., 16%) of the radiation therapy episodes in the M0 sam-
ple were less than or equal to 4 weeks in length. This proportion contrasts with the M1b (i.e.,
78%) and M1c (i.e., 87%) groups. Among M1b and M1c patients the shorter duration radia-
tion therapy episodes were most likely for palliative purposes: to the bone, and also possibly
for other issues like hematuria and local obstructive problems (e.g., obstructive uropathy).
Among patients without a BM code, almost half (47.8%) of the radiation therapy episodes in
the M0 sample were longer than 8 weeks compared to 21.6% in the M1b group and 11.7% in
the M1c group. The higher prevalence of longer duration episodes in M0 is clinically justifiable
as radiation may have been for curative intent.
These findings indicate that a significant portion of the radiation episodes in the M0 group
will represent radiation to the prostate gland and that it will be particularly important to condi-
tion on a BM diagnosis among M0 patients, compared to M1 patients. Prior studies [17, 23]
have questioned the reliability of the BM diagnosis code in claims data as an indicator for a
diagnosis of BM. Our results reinforce this assertion. A validated measure of BM would iden-
tify individuals with non-incident BM in the claims data and could assist with identifying
SREs that occur subsequent to BM, particularly among individuals who were not diagnosed
with incident BM.
We also found differences between the groups when considering the duration of radiation
therapy. In Table 3, more than half of the M1 patients with no BM code during the radiation
episode had a radiation episode of 4 weeks or less compared to 1 in 10 M0 patients with no
BM code during the radiation episode. Among patients with non-BM coded radiation therapy
episodes, the duration requirement served to further isolate potential RtB by focusing on radia-
tion claims that represent a shorter duration of therapy. We expected more episodes of a
shorter duration among M1b and M1c patients compared to M0 patients and thus, that more
episodes would be picked up from M1b and M1c when applying the duration requirement.
Indeed, we find that applying the duration requirement in addition to the BM code require-
ment picks up 3 additional M1b cases with probable RtB for every additional M0 case and 1.4
M1c cases for every M0 case.
differentiation, Charlson Comorbidity Index, osteoporosis pre-diagnosis, performance status and use of
preventive services in the 1 year prior to diagnosis), and other factors including at least 1 month of state buy-
in, region of SEER registry and year of diagnosis. *Time invariant hazard ratio reported as the model satisfied
proportional hazards assumption. **Hazard ratios reported at 1 year and 3 years post-diagnosis as the
models did not satisfy the proportional hazards assumption.
https://doi.org/10.1371/journal.pone.0175956.g002
Skeletal-related events and mortality
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The results regarding the mortality impact of SREs in the M1c group (Fig 1D) warranted
further investigation which we accomplished via follow-up exploratory analyses. The seem-
ingly protective effect of SREs within 2 years of diagnosis could be due to selection into treat-
ment SRE components whereby patients receiving treatment SRE components (i.e., radiation,
bone surgery) were healthier at diagnosis than patients who did not receive these interven-
tions. We found that the survival curves crossed when examining nonPCa-specific mortality as
well as PCa-specific mortality. The crossing of curves in both cases suggests that the eventual
increase in mortality among those with SRE was not likely driven by cancer treatment toxici-
ties, or else we would see a crossing only for the nonPCa mortality model but not for the PCa
mortality model. Thus, it is likely that the effect at the 3-year mark represents the long-term
prognosis of SREs.
There are a few limitations to the study. We do not employ a validated measure of palliative
radiation therapy. To the extent that patients without a BM code received longer duration pal-
liative therapy or shorter duration radiation therapy for curative intent, we may have misclassi-
fied patients based on the length of radiation therapy. The diagnosis of incident BM that is
available from the SEER registry is not validated. While the M1b measure has not been vali-
dated, the information about M1 disease in SEER is considered to be reliable thus we expect
that our general conclusions regarding the differences between M0 and M1 are robust. Unlike
the ICD9 codes used in this study, the new ICD10 set includes codes to identify receipt of palli-
ative radiation although it is too early to determine their reliability. Like ICD9 codes, ICD10
codes may omit other critical features for health services research. In the spirit of a proof-of-
concept, the paper shows that differences in measures developed from billing codes can impact
study conclusions.
Conclusion
Studies have documented the clinical and economic burden of skeletal-related events using
health care claims data. While these data offer advantages for investigating population-level
clinical and cost consequences of SREs, they do not provide the ability to distinguish radiation
to the bone from radiation to the prostate. Among patients who do not have an incident diag-
nosis of metastatic prostate cancer, we found that the definition of radiation to the bone
impacted conclusions regarding the mortality impact of SREs. Future studies should validate
claims-based measures of radiation to the bone to support studies of SREs among cancer
patients, not all of whom will have an incident diagnosis of metastatic disease.
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